Tonlamarsen vs Zilebesiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Angiotensinogen (AGT) · full Hypertension pipeline
Tonlamarsen
Developed by Kardigan under a licence from Ionis Pharmaceuticals
NCT06864104 · Phase 2 · completed
The study randomized 198 participants (206 entered the active run-in) to monthly tonlamarsen or to a single tonlamarsen dose followed by placebo, with participants, care providers, investigators and outcome assessors masked. It had two co-primary outcomes at week 20. Plasma angiotensinogen fell more with monthly dosing (P<0.0001), but office systolic blood pressure fell by 6.7 mm Hg in both groups (P=0.97). One co-primary outcome was met and one was missed, so the result is mixed. The figures are from the peer-reviewed publication (JACC 2026) and the registry's primary outcome list.
Next expected readout: December 2026 · NCT07511361 (registry estimate)
Reported efficacy
Co-primary: change from baseline to week 20 in plasma angiotensinogen and in office systolic blood pressure (between-group differences): Co-primary 1, plasma angiotensinogen change to week 20: monthly tonlamarsen -67.2% vs single dose then placebo -23.0% (LS mean difference -44.1%, 97.5% CI -51.9% to -36.4%; P<0.0001), met. Co-primary 2, office systolic BP change to week 20: -6.7 vs -6.7 mm Hg (LS mean difference -0.1 mm Hg; P=0.97), missed. (mixed)
Result source: NCT06864104
Zilebesiran
Developed by Alnylam Pharmaceuticals and partners
NCT04936035 · Phase 2 · completed
The study randomized 394 participants to placebo or zilebesiran and maintained quadruple blinding, with approximately 60–75 participants per treatment group analyzed for the primary endpoint. The primary clinical endpoint—change in 24-hour ambulatory systolic blood pressure at Month 3—was significantly favorable for zilebesiran versus placebo, supporting strong evidence from this trial.
Next expected readout: September 2030 · NCT07181109 (registry estimate)
Reported efficacy
Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM (Baseline and Month 3): Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM (Baseline and Month 3): Placebo 6.8 millimeters of mercury (mmHg) ± 1.58 vs Zilebesiran 150 mg Q6M -7.3 millimeters of mercury (mmHg) ± 1.49 vs Zilebesiran 300 mg Q6M and Q3M -10.0 millimeters of mercury (mmHg) ± 1.05 vs Zilebesiran 600 mg Q6M -8.9 millimeters of mercury (mmHg) ± 1.52; p=<0.0001 (Placebo vs Zilebesiran 300 mg Q6M and Q3M), p=<0.0001 (Placebo vs Zilebesiran 600 mg Q6M) (met)
Result source: NCT04936035
Results for Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Tonlamarsen | Zilebesiran |
|---|---|---|
| Seated SBP, change | —Not reported | -11.1 vs -0.6−10.5 vs placeboNCT049360355 other results
|
| 24-hour ambulatory SBP, change | —Not reported | -8.9 vs 6.8−15.7 vs placeboNCT0493603511 other results
|
| Seated DBP, change | —Not reported | -6.8 vs -1.2−5.6 vs placeboNCT049360355 other results
|
Seated SBP, change
- Tonlamarsen
- —Not reported
- Zilebesiran
- -11.1 vs -0.6−10.5 vs placeboNCT04936035
5 other results
- -12.8 vs -0.6 NCT04936035
- -10.8 vs -0.6 NCT04936035
- -9.2 vs -0.1 NCT04936035
- -8.2 vs -0.6 NCT04936035
- -9.7 vs -0.1 NCT04936035
24-hour ambulatory SBP, change
- Tonlamarsen
- —Not reported
- Zilebesiran
- -8.9 vs 6.8−15.7 vs placeboNCT04936035
11 other results
- -7.3 vs 6.8 NCT04936035
- -15.7 vs -3.7 NCT05103332
- -10.5 vs -0.7 NCT05103332
- -7.7 vs -3.2 NCT05103332
- -9.9 vs 4.6 NCT04936035
- -9.5 vs 4.6 NCT04936035
- -9.6 vs 4.6 NCT04936035
- -6.5 vs 4.6 NCT04936035
- -15.6 vs -4.6 NCT05103332
- -9.7 vs -1.8 NCT05103332
- -7.6 vs -5.8 NCT05103332
Seated DBP, change
- Tonlamarsen
- —Not reported
- Zilebesiran
- -6.8 vs -1.2−5.6 vs placeboNCT04936035
5 other results
- -8.2 vs -1.2 NCT04936035
- -5 vs -1.2 NCT04936035
- -5.4 vs -0.6 NCT04936035
- -4.1 vs -1.2 NCT04936035
- -5.3 vs -0.6 NCT04936035
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Tonlamarsen: 0 of 4 rows · Zilebesiran: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Zilebesiran |
|---|---|
| Dropout rate | 6.7%300 mg Q3Ma NCT04936035 · Phase 2 show 18 more results4.1%300 mg Q6M NCT04936035 · Phase 2 —300 mg Q3M NCT04936035 · Phase 2 —300 mg Q6M NCT04936035 · Phase 2 6.6%600 mg Q6M NCT04936035 · Phase 2 —600 mg Q6M NCT04936035 · Phase 2 —150 mg Q6M NCT04936035 · Phase 2 —150 mg Q6M NCT04936035 · Phase 2 —DB (Zilebesiran) to SFU or OLE to NCT05103332 · Phase 2 · registry result, not featured evidence · combination —DB (Zilebesiran) to SFU or OLE to NCT05103332 · Phase 2 · registry result, not featured evidence · combination —DB (Zilebesiran) to SFU or OLE to NCT05103332 · Phase 2 · registry result, not featured evidence · combination —DB Period (Zilebesiran) to OLE Per NCT05103332 · Phase 2 · registry result, not featured evidence · combination —DB Period (Zilebesiran) to OLE Per NCT05103332 · Phase 2 · registry result, not featured evidence · combination —DB Period (Zilebesiran) to OLE Per NCT05103332 · Phase 2 · registry result, not featured evidence · combination 4.2%DB Period: Zilebesiran (Add-on to NCT05103332 · Phase 2 · registry result, not featured evidence · combination 9.2%DB Period: Zilebesiran (Add-on to NCT05103332 · Phase 2 · registry result, not featured evidence · combination 5.4%DB Period: Zilebesiran (Add-on to NCT05103332 · Phase 2 · registry result, not featured evidence · combination 8.3%300 mg NCT06423352 · Phase 1/2 · registry result, not featured evidence 8.3%600 mg NCT06423352 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | 0%300 mg Q3Ma NCT04936035 · Phase 2 show 18 more results0%300 mg Q6M NCT04936035 · Phase 2 —300 mg Q3M NCT04936035 · Phase 2 —300 mg Q6M NCT04936035 · Phase 2 0%600 mg Q6M NCT04936035 · Phase 2 —600 mg Q6M NCT04936035 · Phase 2 —150 mg Q6M NCT04936035 · Phase 2 —150 mg Q6M NCT04936035 · Phase 2 —DB (Zilebesiran) to SFU or OLE to NCT05103332 · Phase 2 · registry result, not featured evidence · combination —DB (Zilebesiran) to SFU or OLE to NCT05103332 · Phase 2 · registry result, not featured evidence · combination —DB (Zilebesiran) to SFU or OLE to NCT05103332 · Phase 2 · registry result, not featured evidence · combination —DB Period (Zilebesiran) to OLE Per NCT05103332 · Phase 2 · registry result, not featured evidence · combination —DB Period (Zilebesiran) to OLE Per NCT05103332 · Phase 2 · registry result, not featured evidence · combination —DB Period (Zilebesiran) to OLE Per NCT05103332 · Phase 2 · registry result, not featured evidence · combination —DB Period: Zilebesiran (Add-on to NCT05103332 · Phase 2 · registry result, not featured evidence · combination —DB Period: Zilebesiran (Add-on to NCT05103332 · Phase 2 · registry result, not featured evidence · combination —DB Period: Zilebesiran (Add-on to NCT05103332 · Phase 2 · registry result, not featured evidence · combination —300 mg NCT06423352 · Phase 1/2 · registry result, not featured evidence —600 mg NCT06423352 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 5.3%300 mg Q3Ma NCT04936035 · Phase 2 show 18 more results1.4%300 mg Q6M NCT04936035 · Phase 2 9.3%300 mg Q3M NCT04936035 · Phase 2 6.8%300 mg Q6M NCT04936035 · Phase 2 7.9%600 mg Q6M NCT04936035 · Phase 2 11.8%600 mg Q6M NCT04936035 · Phase 2 0%150 mg Q6M NCT04936035 · Phase 2 6.4%150 mg Q6M NCT04936035 · Phase 2 0%DB (Zilebesiran) to SFU or OLE to NCT05103332 · Phase 2 · registry result, not featured evidence · combination 1.1%DB (Zilebesiran) to SFU or OLE to NCT05103332 · Phase 2 · registry result, not featured evidence · combination 0.5%DB (Zilebesiran) to SFU or OLE to NCT05103332 · Phase 2 · registry result, not featured evidence · combination 2.5%DB Period (Zilebesiran) to OLE Per NCT05103332 · Phase 2 · registry result, not featured evidence · combination 1.6%DB Period (Zilebesiran) to OLE Per NCT05103332 · Phase 2 · registry result, not featured evidence · combination 4.7%DB Period (Zilebesiran) to OLE Per NCT05103332 · Phase 2 · registry result, not featured evidence · combination 2.5%DB Period: Zilebesiran (Add-on to NCT05103332 · Phase 2 · registry result, not featured evidence · combination 0%DB Period: Zilebesiran (Add-on to NCT05103332 · Phase 2 · registry result, not featured evidence · combination 2.7%DB Period: Zilebesiran (Add-on to NCT05103332 · Phase 2 · registry result, not featured evidence · combination 0%300 mg NCT06423352 · Phase 1/2 · registry result, not featured evidence 0%600 mg NCT06423352 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | 300 mg Q3Ma injection site reaction 10.7% (placebo 0%) coronavirus disease of 2019 (covid-19) 8% (placebo 4%) hyperkalaemia 6.7% (placebo 1.3%) NCT04936035 · Phase 2 show 18 more results300 mg Q6M coronavirus disease of 2019 (covid-19) 8.2% (placebo 4%) arthralgia 5.5% (placebo 2.7%) headache 5.5% (placebo 9.3%) NCT04936035 · Phase 2 300 mg Q3M injection site reaction 17.3% (placebo 0%) coronavirus disease of 2019 (covid-19) 12% (placebo 4%) urinary tract infection 12% (placebo 0%) NCT04936035 · Phase 2 300 mg Q6M injection site reaction 11% (placebo 0%) coronavirus disease of 2019 (covid-19) 9.6% (placebo 4%) arthralgia 8.2% (placebo 2.7%) NCT04936035 · Phase 2 600 mg Q6M hyperkalaemia 6.6% (placebo 1.3%) hypertension 6.6% (placebo 6.7%) coronavirus disease of 2019 (covid-19) 5.3% (placebo 4%) NCT04936035 · Phase 2 600 mg Q6M hypertension 11.8% (placebo 6.7%) injection site reaction 11.8% (placebo 0%) coronavirus disease of 2019 (covid-19) 10.5% (placebo 4%) NCT04936035 · Phase 2 150 mg Q6M hyperkalaemia 6.4% (placebo 1.3%) hypertension 5.1% (placebo 6.7%) coronavirus disease of 2019 (covid-19) 3.8% (placebo 4%) NCT04936035 · Phase 2 150 mg Q6M hypertension 11.5% (placebo 6.7%) coronavirus disease of 2019 (covid-19) 9% (placebo 4%) hyperkalaemia 7.7% (placebo 1.3%) NCT04936035 · Phase 2 covid-19 0% (placebo 0%) dizziness 0% (placebo 0%) headache 0% (placebo 0%) NCT05103332 · Phase 2 · registry result, not featured evidence · combination covid-19 0% (placebo 0%) dizziness 0% (placebo 0%) headache 0% (placebo 0%) NCT05103332 · Phase 2 · registry result, not featured evidence · combination covid-19 0% (placebo 0%) dizziness 0% (placebo 0%) headache 0% (placebo 0%) NCT05103332 · Phase 2 · registry result, not featured evidence · combination covid-19 7.6% (placebo 0%) dizziness 6.8% (placebo 0%) hypertension 6.8% (placebo 0%) NCT05103332 · Phase 2 · registry result, not featured evidence · combination hypertension 11.1% (placebo 0%) headache 9.5% (placebo 0%) injection site reaction 7.9% (placebo 0%) NCT05103332 · Phase 2 · registry result, not featured evidence · combination hypertension 9.5% (placebo 0%) dizziness 8.1% (placebo 0%) hyperkalaemia 6.8% (placebo 0%) NCT05103332 · Phase 2 · registry result, not featured evidence · combination covid-19 5.1% (placebo 0%) dizziness 5.1% (placebo 0%) hypertension 5.1% (placebo 0%) NCT05103332 · Phase 2 · registry result, not featured evidence · combination headache 6.3% (placebo 0%) hypertension 6.3% (placebo 0%) injection site reaction 6.3% (placebo 0%) NCT05103332 · Phase 2 · registry result, not featured evidence · combination hypertension 9.5% (placebo 0%) dizziness 7.4% (placebo 0%) hyperkalaemia 5.4% (placebo 0%) NCT05103332 · Phase 2 · registry result, not featured evidence · combination 300 mg headache 16.7% (placebo 0%) pharyngitis 16.7% (placebo 0%) alanine aminotrasferase increased 8.3% (placebo 0%) NCT06423352 · Phase 1/2 · registry result, not featured evidence 600 mg influenza 16.7% (placebo 0%) blood alkaline phosphatase increased 8.3% (placebo 0%) blood potassium increased 8.3% (placebo 0%) NCT06423352 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Zilebesiran
show 11 more results
show 5 more results
show 6 more results
show 11 more results
show 5 more results
show 5 more results
show 5 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 3 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tonlamarsen's landscape · Zilebesiran's landscape